drugset / Trial / NCT00024024
BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
Phase I/II trial to study the effectiveness of BMS-275291 in treating patients who have HIV-related Kaposi's sarcoma. Drugs such as BMS-275291 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
Timeline
- Start
- 2001-08
- Primary completion
- 2003-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rebimastat | Small molecule | 600 mg | Oral |
| Subject | rebimastat | Small molecule | 1200 mg | Oral |